Cirrus Pharmaceuticals, Inc. Expands Service Offerings With The Addition Of cGMP-Compliant Walk-In Stability Chambers
Cirrus Pharmaceuticals, Inc. is excited to announce the expansion of our current capacity for stability storage via the addition of 3 LUWA Walk-in Stability Chambers. Cirrus will add three large capacity chambers, each with 1,100 cubic feet of storage space. These chambers will be cGMP compliant meeting FDA and ICH guideline requirements for stability. "With an increase in our existing and new client sponsor requests for long-term stability storage and testing, expanding our capacity is a logical investment in Cirrus Pharmaceuticals' progression as a contract research service provider" said Jean-Marc Bovet, Ph.D. Executive Senior Vice President.
The new additions include the following storage conditions:
- 25°C / 60% RH storage (long-term conditions)
- 30°C / 65% RH storage (Intermediate conditions)
- 40°C / 75% RH storage (Accelerated Conditions)
With the expansion to cGMP-compliant Walk-In stability chambers, Cirrus will be able to increase its current core capabilities of formulation and strategic product development services for various dosage forms including inhalation, nasal, parenteral, oral, topical and transdermal. In addition, Cirrus will enhance its release testing and stability testing in support of clinical trials, IND and NDA submissions. Validation of the chambers, including temperature and humidity mapping and monitoring systems are on schedule for completion by November of this year.
For additional information visit www.cirruspharm.com or contact BizDev@cirruspharm.com
SOURCE: Cirrus Pharmaceuticals, Inc.